


# **Country support** activities for **TCV introduction**

TyVAC will work with local partners and officials to determine which activities are most advantageous in each country to most effectively and efficiently reach a decision on typhoid conjugate vaccine (TCV) introduction, and if appropriate, meet Gavi, the Vaccine Alliance application deadlines. When appropriate, TyVAC will identify partners to support and lead certain activities.

TyVAC also offers help to see countries through to the actual approval, including intermediary Q&A steps.



### Phase 1: Scoping/Prep and Application



**Phase 1** begins during the first conversation with decision-makers and partners in a country. This phase extends through formal approval of the Gavi TCV application, including responses to Independent Review Committee (IRC) clarifying questions.

6 – 8 MONTHS\*

- Plan a scoping mission to assess decisionmaker interest, share initial information on typhoid burden and TCVs, and meet with key decision-makers and stakeholders.
  - » Determine the level of support that the national immunization program requires to submit a TCV application to Gavi.
- **Outline** key personnel and timelines to collect data and information to complete the Gavi application.
- Review typhoid epidemiologic data and gaps to determine suitability for application.
  - » Assess disease surveillance and water, sanitation, and hygiene (WASH) capabilities.
- Develop specific advocacy materials to share information on typhoid burden, appropriateness of TCVs, health economic information, and relevant drug resistance concerns.
- Support national stakeholder forums that include key public health influencers and decision-makers from national and sub-national levels to discuss contextspecific issues, concerns, and decisions.

- **Support** the decision-making process with the:
  - Provision of technical information, including details on disease surveillance, the World Health Organization (WHO) position paper on TCV, and other global policies.
  - » Preparation of presentations and other materials for any subsequent stakeholder meetings, e.g. National Immunization Technical Advisory Group (NITAG), Inter-Agency Coordinating Committee, or other groups of physicians or immunization specialists.
  - » Advocacy activities, as appropriate, to ensure decision-makers are accurately informed and receiving support.
  - » Estimation of prospective vaccine program costs and/or cost of delivery study in select instances.
  - » Assessment of country specific costeffectiveness analyses in select instances.
- Assist countries with the portal application to Gavi.
- Assist countries with the draft Plan of Action (POA).
- Assist with Gavi planning and budget template, if requested.
- □ **Facilitate** post-application responses from the Gavi sub-team and IRC.

#### Phase 2:

### Introduction

**Phase 2** extends from the time Gavi approves the application for TCV introduction to the actual vaccination via campaign and/or routine immunization.

UP TO 12 MONTHS\*

- Support microplanning activities based on WHO recommendations and new vaccine introduction lessons learned, with an emphasis on equitable access.
- Collaborate with Gavi and UNICEF to develop health care worker training and information, education, and communication (IEC) materials.
- Work with local organizations to ensure all relevant stakeholders, including subnational level officials and pediatricians, are supportive of TCV introduction.
- Ongoing advocacy for TCV introduction stakeholder meetings, including relevant messaging for the local context and WASH, health, and immunization partners.
- Support local partners with social mobilization activities.

- Support adverse event following immunization (AEFI) surveillance training with local partners.
- Conduct site visits to support campaign monitoring.
- Support the post supplementary immunization activity (SIA) coverage survey with WHO.
- Support the vaccination coverage survey (administrative and limited sampling).
- Support countries with development of routine immunization transition planning.

#### Phase 3:

## **Post-Introduction**

	(	ר
· · · · · · · · · · · · · · · · · · ·	1	
	Ľ	

**Phase 3** assesses the successes, the impact, and the lessons learned during TCV introduction. It also aims to collate lessons that can inform future vaccine introduction in other countries.

6	- 12	
MO	NTHS*	

- Assist with post-introduction evaluation to determine the impact of new vaccine introduction on the national immunization program and on the delivery of other childhood vaccines.
- **Help** prepare for post-introduction evaluation.
- Share lessons learned from introduction in order to inform Expanded Programme on Immunization (EPI) programming more broadly and to improve policies, coverage, delivery, and equity
  - » Host regional meetings for countries to share their experience and rationale for TCV introduction.

- Determine actual coverage and factors affecting coverage through post-routine introduction coverage surveys with other partners such as WHO and US Centers for Disease Control and Prevention.
- Compare prospective cost estimates of vaccine delivery versus actual expenses in select instances.
- Conduct operational research, if appropriate, to identify factors affecting certain specific obstacles related to introduction of new vaccine and to provide evidence-based solutions.
- Work with countries to prepare for public health impact studies to sustain TCV influence on typhoid morbidity and mortality post-introduction.

\* These are approximate time periods during which phased activities will be performed. Actual timelines will vary based on context, activities needed, capacity, and resources.







The Typhoid Vaccine Acceleration Consortium (TyVAC) is led by the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH. TyVAC is funded by the Bill & Melinda Gates Foundation.